May 17, 2020

GlaxoSmithKline Plc teams up with GlycoVaxyn

U.K.'s largest drugmaker
exclusive license on vaccines
Admin
1 min
GlaxoSmithKline Plc teams up with GlycoVaxyn
U.K.s largest drugmaker, GlaxoSmithKline Plc will join hands with GlycoVaxyn AG to develop new anti-bacterial conjugate vaccines, an $8 billion market...

U.K.’s largest drugmaker, GlaxoSmithKline Plc will join hands with GlycoVaxyn AG to develop new anti-bacterial conjugate vaccines, an $8 billion market. 

GlycoVaxyn will also get an upfront payment as an equity investment from the drug company, which has an option to get an exclusive license on vaccines they work on during the 3-year collaboration period. 

The company is also eligible to get milestone payments and royalties if the vaccines win regulatory nod. The financial terms of the deal were not disclosed. 

GlycoVaxyn focuses on vaccines against the common severe bacterial infections. Its most advanced program is the vaccine against the Shigella bacterium, which causes dysentery and blood diarrhea. The pre-clinical candidates include vaccines to prevent hospital infections and E.coli.

Philippe Dro, GlycoVaxyn CEO said, “The collaboration with vaccine industry leader confirms the potential of our platform to generate new complex vaccines.” GlycoVaxyn uses recombinant DNA technology that allows it to target bacterial diseases for which effective vaccines don’t yet exist, according to the company.

Investors in GlycoVaxyn include Sofinnova Partners, Index Ventures and Edmond de Rothschild Investment Partners.

GlaxoSmithKline Plc is a British multinational pharmaceutical, biologics, vaccines and consumer healthcare company based in London. It is the world’s the fourth-largest pharmaceutical company measured by 2009 prescription drug sales.

Share article

Jun 21, 2021

Dubai's new smart neuro spinal hospital: need to know

Robotics
smarthospitals
Cancer
Neurology
2 min
The brand new Neuro Spinal Hospital and Radiosurgery Centre has opened in Dubai. We take a look at what this smart hospital offers. 

We take a look at Dubai's new smart hospital. 

What: The Neuro Spinal Hospital and Radiosurgery Centre is a new hospital featuring state-of-the-art technology for spinal, neurosurgical, neurological, orthopaedic, radiosurgery and cancer treatments. The 700 million AED hospital, (equivalent to £138 million), has 114 beds, smart patient rooms, and green spaces for patient rehabilitation, and is four times the capacity of its former premises in Jumeirah.   It is also the UAE’s first hospital to have surgical robots. 

Where: The hospital is located in the Dubai Science Park. Founded in 2005,  Dubai Science Park is home to more than 350 companies from multinational corporations in life sciences, biotechnology and research; over 4,000 people work here each day. 

Who: The UAE's Neuro Spinal Hospital and Radiosurgery Centre was first established in Jumeirah in 2002 by Dr. Abdul Karim Msaddi, as the first as the first "super-specialty" neuroscience hospital. 

Why: With advanced diagnosis and robotics, the hospital will provide care across neuroscience, spine, orthopaedics and oncology for people residing in the UAE, as well as international patients.  

Prof. Abdul Karim Msaddi, Chairman and Medical Director of the hospital, said: “We are proud to bring world-class healthcare services to Dubai and believe our  next-generation hospital will be a game-changer for the emirate’s and the region’s medical industry.

"It will not only significantly increase the availability of specialist neuroscience and radiosurgery treatments and provide better patient care but help attract and develop local and international talent. Investing in the new centre represents our continued faith in the resilience of the region’s economy, as well as a testament to our ongoing drive towards healthcare innovation in the UAE.”

Share article